Replicel Life Sciences Inc REPCF

Primary Symbol: V.RP

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Do we understand what we are voting on ?

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Apr 02, 2024 4:11pm

105 Views

Post# 35966056

RE:RE:RE:RE:Do we understand what we are voting on ?

RPINVESTOR1:

There is no question that this scheme is all about Andrew Schutte and possibly his friend Jamie Mackay getting some or all of their money out of this disaster with little regard for the rest of us shareholders.
In fairness to us as opposed to this ridiculus proposal the proper way to do this is leave Replicel as is and actively sell all of the assets to the highest bidder and share whatever funds are generated.

Andrew must think we are completey daft if we are going to swallow this boondoggle and vote yes.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”